Published in Ann Surg Oncol on October 21, 2005
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res (2012) 4.56
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 2.43
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol (2013) 2.35
Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98
Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology (2009) 1.78
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun (2008) 1.75
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood (2008) 1.74
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun (2009) 1.74
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother (2006) 1.66
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med (2008) 1.56
Toxicities of Immunotherapy for the Practitioner. J Clin Oncol (2015) 1.50
Current concepts of metastasis in melanoma. Expert Rev Dermatol (2008) 1.34
CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther (2010) 1.33
Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) (2013) 1.28
Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer (2016) 1.22
Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm (2010) 1.22
Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res (2012) 1.17
Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol (2008) 1.15
Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A (2014) 1.15
Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci (2009) 1.15
B7-h3 and its role in antitumor immunity. Clin Dev Immunol (2010) 1.14
T-regulatory cell modulation: the future of cancer immunotherapy? Br J Cancer (2009) 1.13
Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine (2007) 1.13
Regulatory T cells and human disease. Clin Dev Immunol (2007) 1.12
The complex role of B7 molecules in tumor immunology. Trends Mol Med (2008) 1.09
Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol (2013) 1.04
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res (2015) 1.02
Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res (2010) 1.01
Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist (2012) 0.99
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. Front Immunol (2013) 0.99
The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg Clin N Am (2010) 0.98
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest (2015) 0.98
Immune regulatory antibodies: are they the next advance? Cancer J (2010) 0.97
Ipilimumab-induced colonic perforation. J Surg Case Rep (2014) 0.96
Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens. J Immunol (2010) 0.96
Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol (2012) 0.96
Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv (2011) 0.96
Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep (2013) 0.94
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) (2014) 0.92
Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases. J Transl Med (2013) 0.91
Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther (2011) 0.90
Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol (2015) 0.89
Translatability scoring in drug development: eight case studies. J Transl Med (2012) 0.89
Combating immunosuppression in glioma. Future Oncol (2008) 0.87
NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. J Immunother Cancer (2015) 0.87
Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs (2008) 0.87
Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation. Ann N Y Acad Sci (2010) 0.86
Use of ipilimumab in the treatment of melanoma. Clin Pharmacol (2013) 0.86
Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clin Cancer Res (2013) 0.85
Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. Clin Cosmet Investig Dermatol (2013) 0.85
The "A, B and C" of Her-2 DNA vaccine development. Cancer Immunol Immunother (2008) 0.85
Monoclonal antibodies in the treatment of pancreatic cancer. Immunotherapy (2009) 0.84
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med (2016) 0.84
NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment. PLoS One (2011) 0.84
Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent Immunity. Immunity (2015) 0.84
Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Ther (2016) 0.83
Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int (2015) 0.82
Combining Vaccines with Conventional Therapies for Cancer. Update Cancer Ther (2007) 0.82
Sarcoma immunotherapy: past approaches and future directions. Sarcoma (2014) 0.81
Anti-CTLA4 Antibody Clinical Trials in Melanoma. Update Cancer Ther (2007) 0.81
Tumor-induced endothelial cell surface heterogeneity directly affects endothelial cell escape from a cell-mediated immune response in vitro. Hum Vaccin Immunother (2013) 0.81
Immunotherapy of melanoma. EJC Suppl (2013) 0.81
Are BiTEs the "missing link" in cancer therapy? Oncoimmunology (2015) 0.81
Design of universal cancer vaccines using natural tumor vessel-specific antigens (SANTAVAC). Hum Vaccin Immunother (2015) 0.80
Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy. Small (2015) 0.80
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clin Cancer Res (2015) 0.80
Modulation of CTLA-4 and GITR for cancer immunotherapy. Curr Top Microbiol Immunol (2011) 0.80
Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies. J Biomed Biotechnol (2011) 0.80
Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opin Pharmacother (2011) 0.80
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer (2016) 0.80
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. J Immunother Cancer (2016) 0.80
Ipilimumab for advanced melanoma: a pharmacologic perspective. J Oncol Pharm Pract (2012) 0.79
Precise identification of immunotherapeutic targets for solid malignancies using clues within the tumor microenvironment-Evidence to turn on the LIGHT. Oncoimmunology (2015) 0.79
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol Oncol (2015) 0.79
Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy. Cancer Immunol Immunother (2015) 0.79
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. Oncologist (2016) 0.78
Ipilimumab pharmacotherapy in patients with metastatic melanoma. Clin Med Insights Oncol (2012) 0.78
Combination immunotherapy: a road map. J Immunother Cancer (2017) 0.77
Emerging options for the treatment of melanoma - focus on ipilimumab. Immunotargets Ther (2014) 0.77
Tumor regression and autoimmunity in cytotoxic T lymphocyte-associated antigen 4 blockade-treated patients. Ann Surg Oncol (2005) 0.77
Beyond adjuvants: immunomodulation strategies to enhance T cell immunity. Vaccine (2015) 0.77
Therapeutic use of Aldara in chronic myeloid leukemia. J Transl Med (2007) 0.76
Role of IL-2 in cancer immunotherapy. Oncoimmunology (2016) 0.76
Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art. Crit Rev Immunol (2014) 0.76
The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma. Cancer Manag Res (2012) 0.76
Trends in cancer immunotherapy. Clin Med Insights Oncol (2010) 0.75
A Case of Ipilimumab-induced Anorectal Fistula. J Crohns Colitis (2015) 0.75
Role of CD152 genetic polymorphisms in the susceptibility to breast cancer. Oncotarget (2017) 0.75
Safety of targeting tumor endothelial cell antigens. J Transl Med (2016) 0.75
Advances in immunotherapy for melanoma management. Hum Vaccin Immunother (2016) 0.75
Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. World J Gastroenterol (2017) 0.75
LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases. Cancer Res (2017) 0.75
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med (2000) 16.09
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2000) 13.13
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
CD28/B7 system of T cell costimulation. Annu Rev Immunol (1996) 10.48
CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 9.94
A cell culture model for T lymphocyte clonal anergy. Science (1990) 9.86
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med (1996) 6.13
The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 5.35
CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med (1996) 4.97
CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol (2002) 4.48
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg (1998) 4.35
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med (1998) 3.70
CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol (1999) 3.49
CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol (1996) 3.40
Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol (1992) 3.37
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res (2000) 2.89
Characterization of CTLA-4 structure and expression on human T cells. J Immunol (1993) 2.68
Guidelines for the safe administration of high-dose interleukin-2. J Immunother (2001) 2.13
Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression. Eur J Immunol (2004) 1.46
Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol (1997) 1.24
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 6.88
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (2003) 5.59
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80